CN100566719C - 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物 - Google Patents

用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物 Download PDF

Info

Publication number
CN100566719C
CN100566719C CNB2004800330307A CN200480033030A CN100566719C CN 100566719 C CN100566719 C CN 100566719C CN B2004800330307 A CNB2004800330307 A CN B2004800330307A CN 200480033030 A CN200480033030 A CN 200480033030A CN 100566719 C CN100566719 C CN 100566719C
Authority
CN
China
Prior art keywords
treatment
group
patients
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800330307A
Other languages
English (en)
Chinese (zh)
Other versions
CN1878557A (zh
Inventor
D·托尔梅伦
B·赫歇尔
H·瓦尔德克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of CN1878557A publication Critical patent/CN1878557A/zh
Application granted granted Critical
Publication of CN100566719C publication Critical patent/CN100566719C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB2004800330307A 2003-11-18 2004-11-15 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物 Expired - Fee Related CN100566719C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03104264.1 2003-11-18
EP03104264 2003-11-18

Publications (2)

Publication Number Publication Date
CN1878557A CN1878557A (zh) 2006-12-13
CN100566719C true CN100566719C (zh) 2009-12-09

Family

ID=34610099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800330307A Expired - Fee Related CN100566719C (zh) 2003-11-18 2004-11-15 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物

Country Status (15)

Country Link
US (1) US7273860B2 (cg-RX-API-DMAC10.html)
EP (1) EP1687006B1 (cg-RX-API-DMAC10.html)
JP (1) JP4824573B2 (cg-RX-API-DMAC10.html)
CN (1) CN100566719C (cg-RX-API-DMAC10.html)
AR (1) AR046454A1 (cg-RX-API-DMAC10.html)
AT (1) ATE378053T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004290925B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0416706A (cg-RX-API-DMAC10.html)
CA (1) CA2545802A1 (cg-RX-API-DMAC10.html)
DE (1) DE602004010172T2 (cg-RX-API-DMAC10.html)
ES (1) ES2297536T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA06005547A (cg-RX-API-DMAC10.html)
PL (1) PL1687006T3 (cg-RX-API-DMAC10.html)
TW (1) TWI344366B (cg-RX-API-DMAC10.html)
WO (1) WO2005049035A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036610A1 (en) * 1999-11-19 2001-05-25 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US11844803B2 (en) * 2017-12-11 2023-12-19 Aetas Pharma Co., Ltd. Renal dysfunction improving drug comprising optical isomer of 1,4-benzothiazepine-1-oxide derivative
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
ES2899200T3 (es) * 2018-06-22 2022-03-10 Synact Pharma Aps Tratamiento de proteinuria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
IL162645A0 (en) * 2002-01-16 2005-11-20 Solvay Pharm Bv solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
TW200306799A (en) * 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
EP1687006B1 (en) 2007-11-14
CA2545802A1 (en) 2005-06-02
BRPI0416706A (pt) 2007-01-16
MXPA06005547A (es) 2006-08-17
US7273860B2 (en) 2007-09-25
DE602004010172T2 (de) 2008-09-11
AR046454A1 (es) 2005-12-07
TWI344366B (en) 2011-07-01
US20050137183A1 (en) 2005-06-23
AU2004290925A1 (en) 2005-06-02
ES2297536T3 (es) 2008-05-01
WO2005049035A1 (en) 2005-06-02
TW200526228A (en) 2005-08-16
PL1687006T3 (pl) 2008-01-31
ATE378053T1 (de) 2007-11-15
DE602004010172D1 (de) 2007-12-27
AU2004290925B2 (en) 2010-07-01
JP4824573B2 (ja) 2011-11-30
HK1097762A1 (zh) 2007-07-06
CN1878557A (zh) 2006-12-13
EP1687006A1 (en) 2006-08-09
JP2007511582A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
JP7562546B2 (ja) 胆汁うっ滞性肝疾患を有する小児対象の成長を増加させる方法
US6693129B2 (en) Compositions and methods for lowering plasma lipoprotein(A) and risk factors of cardiovascular diseases
KR102051031B1 (ko) 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
AU2002211452A1 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
Illingworth et al. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
JP2013528198A (ja) 1型糖尿病の処置
US7273860B2 (en) Method and pharmaceutical compositions for treating or inhibiting renal dysfunctions, diseases or disorders, particularly in diabetic patients
US20200101084A1 (en) Use of nor-bile acids in the treatment of arteriosclerosis
HK1097762B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
JP2002220345A (ja) 脂肪肝改善剤
ES2383889T3 (es) Uso de inhibidores de vasopeptidasa en el tratamiento de nefropatía
HK40129994A (en) Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1097762

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1097762

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091209

Termination date: 20111115